Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$6.66 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.90 million
Earnings per share
-0.316
Dividend per share
N/A
Year To Date Return
43.53%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
⏸️ Investing
Why Zelda Therapeutics Ltd shares jumped 10% higher today
⏸️ Investing
Are the ASX pot stocks running out of puff?
⏸️ Investing
Why these 4 ASX shares surged higher today
⏸️ Investing
Aussie pot stocks are on the charge again
⏸️ Investing
Here's Medlab Clinical Ltd's 'world first' plan to test cannabis on Sydney patients
⏸️ Investing
Why these 4 ASX shares sank like stones today
⏸️ Investing
Zelda Therapeutics Ltd shares rocket 23% higher
⏸️ Investing
Aussie pot stocks are on fire again
⏸️ Investing
Pot stocks are flying high: Here's what you need to know
⏸️ Investing
Is the Australian pot stock sector party over?
⏸️ Investing
Auscann Group Holdings Ltd shares are down 14% in a month
⏸️ Investing
Australian pot stocks: August update
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Feb 2026 | $0.56 | $-0.05 | -8.20% | 26,006 | $0.60 | $0.60 | $0.56 |
| 12 Feb 2026 | $0.61 | $0.01 | 1.65% | 15,058 | $0.61 | $0.61 | $0.61 |
| 11 Feb 2026 | $0.61 | $-0.02 | -3.23% | 20,632 | $0.61 | $0.61 | $0.61 |
| 10 Feb 2026 | $0.62 | $-0.01 | -1.60% | 537 | $0.62 | $0.62 | $0.62 |
| 09 Feb 2026 | $0.63 | $0.01 | 1.61% | 6,196 | $0.62 | $0.63 | $0.62 |
| 06 Feb 2026 | $0.62 | $0.00 | 0.00% | 9,016 | $0.62 | $0.62 | $0.61 |
| 05 Feb 2026 | $0.62 | $0.00 | 0.00% | 2,651 | $0.62 | $0.62 | $0.61 |
| 04 Feb 2026 | $0.62 | $-0.03 | -4.62% | 3,185 | $0.62 | $0.62 | $0.62 |
| 03 Feb 2026 | $0.65 | $0.05 | 8.26% | 1,946 | $0.61 | $0.65 | $0.61 |
| 02 Feb 2026 | $0.61 | $-0.05 | -7.69% | 2,922 | $0.61 | $0.61 | $0.61 |
| 30 Jan 2026 | $0.65 | $0.00 | 0.00% | 8,847 | $0.65 | $0.67 | $0.65 |
| 29 Jan 2026 | $0.65 | $-0.03 | -4.41% | 19,854 | $0.68 | $0.71 | $0.65 |
| 28 Jan 2026 | $0.68 | $-0.04 | -5.52% | 36,887 | $0.74 | $0.75 | $0.68 |
| 27 Jan 2026 | $0.73 | $0.00 | 0.00% | 15,771 | $0.73 | $0.75 | $0.72 |
| 23 Jan 2026 | $0.73 | $0.01 | 1.39% | 48,047 | $0.73 | $0.74 | $0.72 |
| 22 Jan 2026 | $0.72 | $0.02 | 2.84% | 56,606 | $0.71 | $0.78 | $0.71 |
| 21 Jan 2026 | $0.71 | $-0.10 | -12.42% | 78,513 | $0.81 | $0.81 | $0.70 |
| 20 Jan 2026 | $0.81 | $-0.10 | -11.05% | 335,427 | $0.91 | $0.93 | $0.81 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Dec 2025 | Oludare Odumosu | Issued | 386,847 | $100,000 |
As advised by the company. USD, convertible notes Issue
|
| 04 Dec 2025 | Donna O'Donnell | Issued | 193,423 | $50,000 |
As advised by the company. USD 50,000, 193,423 Convertible Notes Issue
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. He has over 15 years' experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Mr Osagie Imasogie has over 30 years of experience in law, finance, business management, healthcare, and the pharmaceutical industry. He is co-founder and Senior Managing Partner of PIPV Capital, a Private Equity firm focused on the Life Sciences sector. Prior to co-founding PIPV Capital, he conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. He has held senior legal, commercial, and R&D positions at pharmaceutical companies including GSK, SmithKline, DuPont Merck, and Endo, where he was founding General Counsel and Senior Vice President for Corporate Development.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Dr Odumosu was Ilera Healthcare's first Chief Operating Officer, leading the design, implementation, and management of Ilera's business operations following its license award in 2017. He oversaw day-to-day operations of Ilera's vertically integrated grower/processor, wholesale, and dispensary and led the formulation of Ilera's proprietary cannabinoid-based product.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of several products across various therapeutic categories. He has nearly 20 years of experience in healthcare, building a foundation of knowledge across marketing and the commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse career in healthcare, life sciences, and public service focused in the Greater Philadelphia area. She was formerly a principal with O'Donnell Associates, working with clients including non-profit organisations, universities, and life science companies such as Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 9.54% |
| Sunset Capital Management Pty Ltd | 573,725 | 4.82% |
| Securities Vault Pty Ltd | 488,059 | 4.10% |
| Quincy Street Capital Llc | 456,622 | 3.84% |
| Mr Zoltan Kerekes | 393,168 | 3.30% |
| Osagie Imasogie | 393,168 | 3.30% |
| Sharri J Rochlin | 393,168 | 3.30% |
| Ms Lisa Gray | 381,988 | 3.21% |
| BNP Paribas Nominees Pty Ltd | 341,932 | 2.87% |
| Mera I Llc\C | 332,479 | 2.79% |
| Mr Torsten M Geers | 307,454 | 2.58% |
| Mr Steve Shapiro | 302,571 | 2.54% |
| Mara Gordon | 252,242 | 2.12% |
| Mr Saul Shorr Mrs Margaret Shorr | 151,285 | 1.27% |
| Dr Chanda Latrice Macias | 146,479 | 1.23% |
| Mera Ii Llc\C (i) | 133,372 | 1.12% |
| Oludare Odumosu | 131,766 | 1.11% |
| Citicorp Nominees Pty Limited | 121,342 | 1.02% |
| Mr Daniel Hexter Mrs Shannon Hexter | 103,389 | 0.87% |
| Geers Egag Llc | 85,715 | 0.72% |
